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a  b  s  t  r  a  c  t
Triazole fungicides are used broadly for the control of infectious diseases of both humans
and plants. The surge in resistance to triazoles among pathogenic populations is an emer-
gent issue both in agriculture and medicine. The non-rational use of fungicides with
site-speciﬁc modes of action, such as the triazoles, may increase the risk of antifungal
resistance development. In the medical ﬁeld, the surge of resistant fungal isolates has been
related to the intensive and recurrent therapeutic use of a limited number of triazoles for
the  treatment and prophylaxis of many mycoses. Similarities in the mode of action of tri-
azole  fungicides used in these two ﬁelds may lead to cross-resistance, thus expanding the
spectrum of resistance to multiple fungicides and contributing to the perpetuation of resis-
tant  strains in the environment. The emergence of fungicide-resistant isolates of human
pathogens has been related to the exposure to fungicides used in agroecosystems. Exam-
ples  include species of cosmopolitan occurrence, such as Fusarium and Aspergillus, which
cause diseases in both plants and humans. This review summarizes the information about
the  most important triazole fungicides that are largely used in human clinical therapy and
agriculture. We  aim to discuss the issues related to fungicide resistance and the recom-
mended strategies for preventing the emergence of triazole-resistant fungal populations
capable of spreading across environments.©  2016 Sociedade Bras
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Introduction
Fungicides are a key component in human therapy and
the control of plant diseases caused by fungi that threaten
human health and crop production.1–5 Among the several
types of fungicides, the azole group (triazole and imidazole
derivatives) was ﬁrst introduced in the 1970s.3 Since then,
azoles, especially the triazoles, have been widely used for
the control of fungal diseases of several plants and human
mycoses.6–8 As opposed to other systemic fungicides, the
speciﬁc site of action of triazoles is an inherent advan-
tage that has led to improved control efﬁcacy of the target
fungus.9,10 However, experience has shown that these com-
pounds are prone to resistance in the pathogenic population,
especially without the following of recommended practices
that are aimed at prolonging the effectiveness of these
fungicides.9,11,12
In this context, the efﬁcacy of triazole fungicides can be
affected due to cross-resistance or when an isolate devel-
ops resistance to all fungicides in a chemical group.13,14
Some authors have also suggested that cross- and multidrug-
resistance may be driving forces in the development of
resistance in fungi that are at the interfaces of agroecosys-
tem, domestic, and hospital environments.15,16 For instance,
emerging fungi in clinical environments include saprophytic
or plant pathogenic fungi that have previously exposed to tri-
azole fungicides and end up spreading into the environment
and infecting humans.6,17–19
In this mini review, we summarize key aspects of the triaz-
oles for therapeutic use and discuss the possible link between
triazole-resistant clinical isolates and the widespread use of
triazole fungicides for the control of fungal diseases, which
would have a major impact in agriculture.
Basic  aspects  and  therapeutic  use  of  triazoles
The azole fungicides are of synthetic origin and are char-
acterized by the presence of an aromatic ﬁve-membered
heterocycle. These include triazoles (two carbon atoms and
three nitrogen atoms), imidazoles (three carbon atoms and
two nitrogen atoms), and thiazoles (three carbon atoms, one
nitrogen atom and one sulfur atom).20 The characteristics of
the azole rings, which are distinguished by the number of
nitrogen and sulfur atoms, change the physical and chem-
ical properties, toxicity, and therapeutic efﬁcacies of these
compounds.21 Therefore, the addition of different substitutes
to the pristine 1,2,4-triazole molecule inﬂuences its fungicide
or fungistatic effect.
Triazoles affect the biosynthesis of ergosterol, a funda-
mental component of the fungal cell plasma membrane.22
The main target of antifungal azole drugs is lanosterol 14-
 demethylase (Erg11 protein), a cytochrome P450 enzyme
that is involved in the conversion of lanosterol to 4,4-
dimethylcholesta-8(9),14,24-trien-3-ol. The azole agents link
to this enzyme using the aromatic ﬁve-membered heterocycle
and thereby inhibit the cytochrome P450 catalytic activity.9,23
The absence of ergosterol and the increase of intermediate
compounds alter fungal membrane integrity as well as cell
morphology, which inhibits fungal growth.24,25 b i o l o g y 4 7 (2 0 1 6) 793–799
Triazoles are among the most common systemic fungicides
used in the control of plant diseases. Triazoles are absorbed
and translocated in the plant, where they act preventively
(before infection) or curatively (in the presence of symptoms)
by affecting germ tube and appressoria formation or hausto-
ria development and/or mycelial growth.26,27 By widening the
window of protection beyond protectant fungicides, which act
only preventatively and are not translocated, the advantages
of triazoles represent a breakthrough in increasing the produc-
tivity of various crops affected by fungal diseases.2 Around a
third of all fungicides used for the protection of crop yields
include triazoles, among which more  than 99% are inhibitors
of demethylation (DMI).28 However, triazole fungicides are also
known to present long-term stability, allowing them to remain
active in certain ecological niches, such as soil and water, for
several months.2,29
The number of antifungals available in the medical ﬁeld for
the treatment of systemic infections is relatively limited com-
pared to those used for controlling diseases in plants, which
is mainly due to problems related to erratic efﬁcacy, drug tox-
icity, and intrinsic resistance.30 These compounds are usually
effective in both topical and prophylactic treatments of inva-
sive fungal infections.31 However, new triazoles that are less
toxic to humans and with more  speciﬁc targets have been
investigated.32–34 The ﬁrst generation of triazoles for human
therapy included itraconazole and ﬂuconazole. The second
generation is represented by voriconazole and posaconazole,
which proved to be less toxic, safer, and with a broader spec-
trum of activity, including activity against fungi that were
resistant to the previous generation.35,36 Presently, isavucona-
zole, ravuconazole, and albaconazole are being investigated
in phase III clinical trials as extended-spectrum triazoles with
fungicidal activity against a wide number of clinically impor-
tant fungi.
Development  and  monitoring  of  triazole  resistance
The development of resistance to triazoles as a result of selec-
tive pressure by the continued use of regular or sub-regular
dosages of fungicide is typically quantitative and expressed by
a gradual change in the frequency of resistant isolates.10 The
main mechanisms involved have been reviewed and relate
to the overexpression of the CYP51 gene due to mutations
(insertions or duplications) in the promoter region and an
increase in molecular efﬂux by ABC transporters caused by the
overexpression of genes coding for membrane transport.9,37,38
Recently, a study that examined A. fumigatus isolates from
a range of clinical environments suggested point mutations
of CYP51 and TR34/L98H genomic regions in isolates obtained
from patients with long term use of triazole-based therapy for
the treatment of chronic aspergillosis.16
A key element in the sustainable use of fungicides is to
monitor the sensitivity of the pathogen population to a cer-
tain compound.39–41 There are a number of direct and indirect
methods recommended for speciﬁc fungi that are aimed at
estimating the EC50 (effective concentration at which 50% of
fungal growth is inhibited) and MIC (minimum inhibitory con-
centration) values.10,42–45
In the medical ﬁeld, the surveillance and prevention of
resistance to antifungal agents have been subject to many
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Table 1 – Pathogenic fungi with intrinsic or developed resistance to triazoles for human therapeutic use.
Triazole Fungi References
Itraconazole Aspergillus fumigatus;  Fusarium solani; F. oxysporum;  Zygomycetes; Candida spp. 83–87,63
Fluconazole Candida spp.; Saccharomyces cerevisiae;  Trichosporon spp.; Fusarium solani; F. oxysporum;
Scedosporium spp.; Penicillium spp.; Bipolaris australiensis; B. hawaiiensis;  B. spicifera;
Aspergillus spp.; Dermatophytes; Zygomycetes; dimorphic fungi; Cryptococcus neoformans
73,84,85,88–93
Voriconazole Aspergillus fumigatus;  Zygomycetes Trichosporon spp.; Penicillium spp. 86,87,94,95
Posaconazole Aspergillus fumigatus 96
Ravuconazole Fusarium solani; F.oxysporum; Zygomycetes; Pseudallescheria spp.; Scedosporium spp.;
Acremonium spp.; Sporothrix schenckii;  Scopulariopsis spp.; Paecilomyces spp.
20,34












































estrictive actions in recent years. More  speciﬁcally, the
DA (Food and Drug Administration) and the EMA (Euro-
ean Medicines Agency) regulate and approve the use of
ntimicrobials in North America and Europe, respectively.46
imultaneously, the Clinical and Laboratory Standards Insti-
ute (CLSI), together with the Subcommittee on Antifungal
usceptibility Testing (AFST) of the European Committee for
ntimicrobial Susceptibility Testing (EUCAST), publish in vitro
est protocols periodically for monitoring fungi sensibility to
ntifungal agents of clinical and veterinary use. These actions
llow for the standardization of parameters for the evaluation
f in vitro resistance in the laboratory. However, these actions
nd protocols do not involve the monitoring of resistance of
lant pathogenic fungi, thus challenging the use of antifungal
gents in clinical therapy.
In agriculture, the Fungicide Resistance Action Committee
FRAC), a technical group maintained by the industry, pro-
ides guidelines for the management of fungicide resistance,
uch as the need to estimate a baseline resistance level in iso-
ates sampled from the population prior to the commercial use
f a fungicide.47 During commercial use, reports of failures
n disease control and detection of resistant isolates (those
ith sensitivity levels lower than the baseline) are indicators
f the risk of developing fungicide resistance.47 Periodically,
nformation is provided by the FRAC about the risk of plant
athogens that ranges from low to high. Currently, many  stud-
es are known that report steadily increasing resistance to
riazoles in plant pathogenic fungi.48
riazole  resistance  in  clinical  isolates  and  agricultural  use
n the medical ﬁeld, the ﬁrst report of DMI’s resistance in
. fumigatus isolates dates back more  than three decades
go. However, the resistance to itraconazole by Aspergillus
pp. from the clinical environment was ﬁrst reported in
997 for three isolates obtained from California in the
ate 1980s.49 The prescription of triazoles as a preferential
hoice for the treatment of patients with respiratory dis-
ases has been considered to contribute to the development
f resistance to this group of fungicides.10,50,51 Multidrug-
esistance (MDR)52 is considered to be the cause of the
ailure of a wide range of antifungal agents available on
he market.53,54 As an emergent fungus in clinical envi-
onments, A. fumigatus holds a history of cross-resistance
nd multi-resistance to azoles.55 It is probable that millions
f people are not effectively treated due to infections by97
fungi exhibiting antifungal resistance, among which 4.8 mil-
lion cases are related only to the species of Aspergillus.56
The triazole antifungals commonly used in the medical
ﬁeld for the treatment of fungal diseases and pathogens
that have exhibited some level of resistance are listed in
Table 1.
It has been shown that exposure of environmental fungi
to triazole fungicides may cause shifts from susceptible to
resistant populations, especially in the absence of adaptive
costs which may facilitate the spread of resistant popula-
tions into diverse environments.57 The surge of “emerging
fungi” in the medical ﬁeld or fungi that are otherwise harmless
to humans, such as the zygomycetes and other hyaline ﬁla-
mentous fungi,2,57 has led some authors to hypothesize that
other mechanisms may be leading to resistance, such as the
large amount of fungicides used in agroecosystems.7,58,59 This
hypothesis was initially suggested by studies conducted in the
Netherlands13 and later corroborated by studies conducted
in Spain,60 Belgium,13 Norway,13 Great Britain,61 Denmark,62
France,63 China,64 Italy,65 Austria,65 and India.28
A few studies have jointly examined the sensitivity of
isolates that cause diseases in both plants and humans to
triazoles. These studies suggested that the selection of fungi-
cides with a similar mode of action as those used in human
drug therapy for triazole-resistant isolates could contribute
to the development of multi-resistant populations.66,67 The
development of cross-resistance to triazoles and the low num-
ber of triazoles recommended for human therapy relative to
the high number of triazoles used in agriculture may affect
triazole efﬁcacy for human therapy.6,10 For instance, the fun-
gus Colletotrichum graminicola that causes anthracnose of corn
plants is an emerging pathogen in humans. Resistance to
tebuconazole as well as to multiple other azole antifungals has
been reported in plant pathogenic populations used in clini-
cal medicine.68,69 Similarly, cross-resistance to triazoles was
observed in clinical isolates of Candida albicans and agricultural
environmental yeasts.70
Several other fungi have been found in association with
human and animal diseases, including species of several
genera such as Bipolaris, Macrophomina,  Aspergillus,  Fusa-
rium, Alternaria and Mucor18,71–73 (Table 2). The pathogenicity
of clinical isolates of the Fusarium solani species complex
was conﬁrmed in plants of the Cucurbitacea family, which
exhibited similar aggressiveness to isolates originating from
diseased plants.17 Criptococcus neoformans is also found in dif-
ferent environmental niches, such as plants and animals.74
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Table 2 – Main genera of fungi reported as the causative agents of diseases in plants and in humans.
Genus Species References
Fusarium F. dimerum;  F. verticilliodies; F. solani;  F. oxysporium;  F. gramminearum;  F. poae;  F.
sporotrichoides; F. culmorum
18,98,99
Alternaria A. alternate 100,101
Aspergillus A. ﬂavus; A. par
B. asiticus; A. terreus
18,98,102–104
Curvularia C. lunata 105
Cladosporium C. cladosporioides 106,107
Colletotrichum C. gloeosporioides,  C. coccodes 68,108
Mucor M. piriforms 109,110
Absidia Absidia spp. 18,109
Rhizopus R. arrizhus 109,111
cifera
rMacrophomina M. phaseolina
Bipolaris B. australiensis; B. hawaiiensis; B. spi
Fluconazole is the most prevalent clinical antifungal used to
treat cryptococcosis.75 However, the continued use of this anti-
fungal is an increasing concern due to the frequency of isolates
resistant to triazoles used in human therapeutic use.76 There
is a need for attention to azole resistance and optimal ther-
apy in regions with high incidence of cryptococcosis, such
as the Asian-Paciﬁc region (5.1–22.6%), Africa/Middle-East
(7.0–33.3%), and Europe (4.2–7.1%).77 In addition to ﬂuconazole
resistance in these regions, the new point of mutation in the
ERG11 gene of C. neoformans afforded resistance to voricona-
zole (VRC).78 In these cases, the spread of isolates exhibiting
resistance to triazoles into the environment and those capable
of causing human diseases may affect the efﬁcacy of therapeu-
tic control with fungicides of the same group, especially in the
presence of cross-resistance.79
The mutagenesis in TR34/L98H in azole-resistant Aspergillus
may have originated due to the use of triazole fungicides in
agroecosystems.14,28,80 Such mutation was detected in 89% of
A. fumigatus-resistant isolates from air samples, ﬂowers, and
soils from hospital areas.6 Microsatellite sequencing of clin-
ical and environmental isolates that lead to the TR34/L98H
mutation revealed high genetic homology, which suggests a
common ancestor.6,13
Future  directions
Triazole antifungals largely used in plant protection are also
important as antifungal treatments in the human medical
ﬁeld even though they possessing structural differences. How-
ever, sensitive populations that co-inhabit environments may
be reduced by the selection of isolates resistant to fungicides.
Fungi arising from agricultural ecosystems as opportunistic
pathogens may carry cross-resistance to triazoles used in the
medical ﬁeld. The restricted number of antifungal agents for
clinical use, which contrasts with the large number of agricul-
tural fungicides with similar modes of action, may be a risk
factor that limits the success of the therapeutic use of these
drugs.
Currently, genome-wide studies, together with novel T-
cell-based therapeutic approaches for the prophylaxis and
treatment of opportunistic fungal infections, have promising
avenues of research in the detection of potentially new anti-
fungal targets.81,82 Thus, different strategies should be the
main goals of the pharmaceutical industry.72
73,112
Given that the search for new antifungal drugs is a lengthy
process, the combination of drugs to achieve synergistic
effects is currently adopted as an alternative. This approach
includes the combination of drugs with distinct mechanisms
of action that may enhance efﬁcacy by combining low concen-
trations of both antifungal agents, thus diminishing the risk
of developing resistance.
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